19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)

Autor:	Amirrtha Srikanthan, David W. Cescon, P. Bedard, I. Li, J. Edwards, Linda Hagerman, Caroline A. Lohrisch, M. Mates, N. Drummond-Ivars, L. Rastgou, Lesley Seymour, David Warr, Dongsheng Tu, M. Rushton, Andrew Robinson, Karen A. Gelmon, John Hilton, Xinni Song
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Breast cancer business.industry Internal medicine medicine HER2 negative Weekly paclitaxel In patient Hematology medicine.disease business
Zdroj:	Annals of Oncology. 31:S7
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.01.028
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::66e00738f039051b865bcb4fc8f94d79 https://doi.org/10.1016/j.annonc.2020.01.028 Zobrazit plný text záznamu